Targeted Stimulation of Dendritic Cells via MDK-ALK -STAT3 Inhibition by Dendritic Cell-derived Exosomes

Open Access

Issue		BIO Web Conf. Volume 237, 2026 2026 8^th International Conference on Biotechnology and Biomedicine (ICBB 2026)


Article Number		01013
Number of page(s)		7
Section		Molecular and Cellular Pathophysiology
DOI		https://doi.org/10.1051/bioconf/202623701013
Published online		10 June 2026

Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209–249. [Google Scholar]
Casal-Mouriño, A., et al., Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res, 2021. 10(1): p. 506–518. [Google Scholar]
Liang, H., et al., Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study. Thorac Cancer, 2019. 10(7): p. 1521–1532. [Google Scholar]
Zhang, M., et al., Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer, 2025. 24(1): p. 136. [Google Scholar]
Sharma, P., et al., Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 2017. 168(4): p. 707–723. [Google Scholar]
Khosravi, G.R., et al., Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun (Lond), 2024. 44(5): p. 521–553. [Google Scholar]
Schenkel, J.M., et al., Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) T cells in tumor-draining lymph nodes. Immunity, 2021. 54(10): p. 2338–2353.e6. [Google Scholar]
Dammeijer, F., et al., The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell, 2020. 38(5): p. 685–700.e8. [Google Scholar]
Chen, J., et al., Dysfunction of dendritic cells in tumor microenvironment and immunotherapy. Cancer Commun (Lond), 2024. 44(9): p. 1047–1070. [Google Scholar]
Zhou, J., et al., STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity. Nature, 2025. 643(8071): p. 519–528. [Google Scholar]
Catena, X., et al., Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade. Nature Cancer, 2025. 6(4): p. 682–701. [Google Scholar]
Plebanek, M.P., et al., A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression. Sci Immunol, 2024. 9(95): p. eadi4191. [Google Scholar]
Pyo, K.H., et al., Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK–Positive Human Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017. 12(3): p. 491–500. [Google Scholar]
Fu, S., et al., Exosome engineering: Current progress in cargo loading and targeted delivery. NanoImpact, 2020. 20. [Google Scholar]
Tian, T., et al., Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials, 2018. 150: p. 137–149. [Google Scholar]
Wang, Y., et al., Locoregional Immune Checkpoint Blockade and Remodeling of Lymph Nodes by Engineered Dendritic Cell-Derived Exosomes for Suppressing Tumor Progression and Metastasis. Adv Sci (Weinh), 2025. 12(23): p. e2500139. [Google Scholar]
Sposito, M., et al., Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications. Expert Rev Clin Immunol, 2024. 20(8): p. 959–970. [Google Scholar]
Schenk, E.L., Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions. Transl Lung Cancer Res, 2023. 12(2): p. 322–336. [Google Scholar]
Montecalvo, A., et al., Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood, 2012. 119(3): p. 756–66. [Google Scholar]
Théry, C., et al., Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol, 2002. 3(12): p. 1156–62. [Google Scholar]
Liu, Y., et al., Binding of the monoclonal antibody RP215 to immunoglobulin G in metastatic lung adenocarcinomas is correlated with poor prognosis. Histopathology, 2015. 67(5): p. 645–53. [Google Scholar]
Zitvogel, L., et al., Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med, 1998. 4(5): p. 594–600. [Google Scholar]
Lindenbergh, M.F.S., et al., Dendritic cells release exosomes together with phagocytosed pathogen; potential implications for the role of exosomes in antigen presentation. J Extracell Vesicles, 2020. 9(1): p. 1798606. [Google Scholar]
Simoni, Y., et al., Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature, 2018. 557(7706): p. 575–579. [Google Scholar]
Iso, H., et al., Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. Onco Targets Ther, 2023. 16: p. 465–470. [Google Scholar]
Shimada, M., et al., A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation. Respir Investig, 2018. 56(4): p. 365–368. [Google Scholar]
Guo, Y., et al., Long-term survival of an ALK fusion lung adenocarcinoma patient with high mutation burden and microsatellite instability high: a case report. Anticancer Drugs, 2025. 36(5): p. 427–431. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.